


Supplemental Digital Content 1

Supplement to: Effects of adjunctive brexpiprazole on individual depressive symptoms and functioning in patients with major depressive disorder and anxious distress: post hoc analysis of three placebo-controlled studies.

FIGURE S1. Mean change in MADRS item scores from baseline over 6 weeks of treatment with adjunctive brexpiprazole (2 mg or 2–3 mg) or adjunctive placebo, stratified by the presence or absence of anxious distress at baseline.



^an-values for ADT + placebo/ADT + brexpiprazole. *p<0.05, **p<0.01, ***p<0.001 versus ADT + placebo; MMRM.

ADT, antidepressant treatment; LS, least squares; MADRS, Montgomery–Åsberg Depression Rating Scale; MMRM, mixed model for repeated measures; SE, standard error.